ALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following...
InspireMD enrolls first patient in CGUARDIANS II trial for CGuard Prime Stent System in TCAR procedures.Quiver AI SummaryInspireMD, Inc. has announced the enrollment of the first patient in its CGUARDIANS...
InspireMD appoints Scott R. Ward to its Board, enhancing expertise ahead of potential U.S. approval for CGuard Prime stent.Quiver AI SummaryInspireMD, Inc. has announced the appointment of Scott R. Ward,...
NAMSA , a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc . (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention...
- Generated 47.8% growth in CGuard™ revenue year-over-year - - Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a...
- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, Aug. 02, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR),...
Credited with performing the first ever endovascular repair procedure in 1990...
Successful live case transmission again demonstrated CGuard’s™ differentiated patient protection features and ease of use...
Live case transmission designed to demonstrate ease-of-use and exceptional patient safety features of CGuard™ Embolic Prevention System (EPS) ...
- 20% growth in CGuard™ revenue Year-over-Year - - C-Guardian FDA IDE Trial Completes First European Enrollment - - Held...